Platelet-activating factor acetylhydrolase activity in human tissues and blood cells

Lipids ◽  
1991 ◽  
Vol 26 (12) ◽  
pp. 979-985 ◽  
Author(s):  
Diana M. Stafforini ◽  
Stephen M. Prescott ◽  
Guy A. Zimmerman ◽  
Thomas M. McIntyre
Keyword(s):  
Blood Cells ◽  
Platelet Activating Factor ◽  
Human Tissues ◽  
Platelet Activating Factor Acetylhydrolase

Red Blood Cells Highly Express Type I Platelet-Activating Factor-Acetylhydrolase (PAF-AH) Which Consists of the α1/α2 Complex

2005 ◽  
Vol 138 (4) ◽  
pp. 509-517 ◽  
Author(s):  
Ken Karasawa ◽  
Mariko Shirakura ◽  
Ayako Harada ◽  
Noriko Satoh ◽  
Kazuaki Yokoyama ◽  
...  
Keyword(s):  
Red Blood Cells ◽  
Blood Cells ◽  
Platelet Activating Factor ◽  
Type I ◽  
Platelet Activating Factor Acetylhydrolase

scholarly journals Deficiency of plasma platelet-activating factor acetylhydrolase: Roles of blood cells

1996 ◽  
Vol 53 (3) ◽  
pp. 158-164 ◽  
Author(s):  
Hidemi Yoshida ◽  
Kei Satoh ◽  
Masayuki Koyama ◽  
Makoto Hiramoto ◽  
Shigeru Takamatsu
Keyword(s):  
Blood Cells ◽  
Platelet Activating Factor ◽  
Platelet Activating Factor Acetylhydrolase

A Mutation in Plasma Platelet-activating Factor Acetylhydrolase (Val279Phe) Is a Genetic Risk Factor for Cerebral Hemorrhage but not for Hypertension

1998 ◽  
Vol 80 (09) ◽  
pp. 372-375 ◽  
Author(s):  
Hidemi Yoshida ◽  
Tadaatsu Imaizumi ◽  
Koji Fujimoto ◽  
Hiroyuki Itaya ◽  
Makoto Hiramoto ◽  
...  
Keyword(s):  
Risk Factor ◽  
Genetic Risk ◽  
Platelet Activating Factor ◽  
Vascular Diseases ◽  
Genetic Risk Factor ◽  
Brain Hemorrhage ◽  
Platelet Activating Factor Acetylhydrolase ◽  
Paf Acetylhydrolase ◽  
Polymerase Chain ◽  
The Difference

SummaryPlatelet-activating factor (PAF) acetylhydrolase is an enzyme that inactivates PAF. Deficiency of this enzyme is caused by a missense mutation in the gene. We previously found a higher prevalence of this mutation in patients with ischemic stroke. This fact suggests that the mutation might enhance the risk for stroke through its association with hypertension. We have addressed this hypothesis by analyzing the prevalence of the mutation in hypertension. We studied 138 patients with essential hypertension, 99 patients with brain hemorrhage, and 270 healthy controls. Genomic DNA was analyzed for the mutant allele by the polymerase-chain reaction. The prevalence of the mutation was 29.3% (27.4% heterozygotes and 1.9% homozygotes) in controls and 36.2% in hypertensives and the difference was not significant. The prevalence in patients with brain hemorrhage was significantly higher than the control: 32.6% heterozygotes and 6.1% homozygotes (p <0.05). PAF acetylhydrolase deficiency may be a genetic risk factor for vascular diseases.

scholarly journals Consumption of Enriched Yogurt with PAF Inhibitors from Olive Pomace Affects the Major Enzymes of PAF Metabolism: A Randomized, Double Blind, Three Arm Trial

Biomolecules ◽  
2021 ◽  
Vol 11 (6) ◽  
pp. 801
Author(s):  
Maria Detopoulou ◽  
Agathi Ntzouvani ◽  
Filio Petsini ◽  
Labrini Gavriil ◽  
Εlizabeth Fragopoulou ◽  
...  
Keyword(s):  
Platelet Activating Factor ◽  
Lipid Mediator ◽  
Olive Pomace ◽  
Double Blind ◽  
Promising Alternative ◽  
Catabolic Enzymes ◽  
Platelet Activating Factor Acetylhydrolase ◽  
The Impact ◽  
By Products ◽  
Apparently Healthy

Platelet-activating factor (PAF), a proinflammatory lipid mediator, plays a crucial role in the formation of the atherosclerotic plaque. Therefore, the inhibition of endothelium inflammation by nutraceuticals, such as PAF inhibitors, is a promising alternative for preventing cardiovascular diseases. The aim of the present study was to evaluate the impact of a new functional yogurt enriched with PAF inhibitors of natural origin from olive oil by-products on PAF metabolism. Ninety-two apparently healthy, but mainly overweight volunteers (35–65 years) were randomly allocated into three groups by block-randomization. The activities of PAF’s biosynthetic and catabolic enzymes were measured, specifically two isoforms of acetyl-CoA:lyso-PAF acetyltransferase (LPCATs), cytidine 5′-diphospho-choline:1-alkyl-2-acetyl-sn-glycerol cholinephosphotransferase (PAF-CPT) and two isoforms of platelet activating factor acetylhydrolase in leucocytes (PAF-AH) and plasma (lipoprotein associated phospholipase-A2, LpPLA2). The intake of the enriched yogurt resulted in reduced PAF-CPT and LpPLA2 activities. No difference was observed in the activities of the two isoforms of lyso PAF-AT. In conclusion, intake of yogurt enriched in PAF inhibitors could favorably modulate PAF biosynthetic and catabolic pathways.

Sign in / Sign up

Export Citation Format

Share Document